Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）

Chronic Hepatitis b Clinical Trial

Official title:

Efficacy and Safety of Antiviral Therapy With Peg-interferon for Chronic Hepatitis B Complicated With Nonalcoholic Fatty Liver Disease（OCEAN PROJECT）

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06368882
• Other study ID #: Yongping _Chen
• Status: Recruiting
• Phase: Phase 4
• Start date: January 1, 2024
• Est. completion date: December 31, 2028

Study information

• Verified date: February 2024
• Source: First Affiliated Hospital of Wenzhou Medical University
• Contact: Yongping Chen, Professor
• Phone: 13505777281
• Email: 13505777281[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multicenter, open-label, non-randomized controlled real-world study to explore the efficacy and safety and to accumulate more evidence-based medical data of an antiviral treatment programme for chronic viral hepatitis B with nonalcoholic fatty liver disease.

A total of 1500 patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease are divided into test group (1000 patients receiving PEG-IFNα-based antiviral therapy (combined NAs or Peg-IFNα monotherapy) and control group（500 patients receiving NAs monotherapy） according to their treatment intention. Laboratory and medical data from specified follow-up points are collected, and adverse events and drug combinations are recorded detailly.

The primary efficacy indicator is HBsAg clearance at 48 weeks of treatment, and the secondary indicators included: (1) HBsAg clearance at 96 weeks of treatment, (2) Cumulative HBsAg clearance at week 24、120、144、168、192、216 and 240; (3) The improvement of liver function level(ALT, AST, TBIL, etc.), blood lipid (TC, TG, LDL-C, HDL-C, etc.), fasting blood glucose, insulin resistance index (HOMA-IR), controlled attenuation parameter, body mass index , liver stiffness measurement, liver histological fibrosis, FIB-4 index from baseline; (4)Incidence of liver cirrhosis and hepatocellular carcinoma during follow-up.

The security assessment includes adverse events, vital signs, and imaging.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1500
• Est. completion date: December 31, 2028
• Est. primary completion date: December 31, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Age of 18-60 years old, male or female (including 18 and 60 years old);

2. meet the diagnostic criteria for chronic hepatitis B in the Guidelines for the prevention and treatment of chronic hepatitis B (2022 edition), and meet the imaging diagnostic criteria for fatty liver in the guidelines for the prevention and treatment of non-alcoholic fatty liver disease (2018 Update edition).

3. serum HBsAg positive >6 months;

4. NAs treatment: baseline HBsAg=1500 IU/ml, HBeAg negative, HBV DNA negative (not detected);

5. IHC initial treatment: baseline HBsAg<1000 IU/ml, HBeAg negative, HBV DNA negative (undetectable), ALT and AST persistently normal (ULN: <50 IU/L in men, <40 IU/L in women);

6. a negative serum pregnancy test within 24 hours before the first dose (for women of reproductive age);

7. willing to receive treatment and signed informed consent.

Exclusion Criteria:

1. co-infection with active hepatitis A, C, D, E and/or HIV; Or combined with drug-induced liver injury, inherited metabolic liver disease, autoimmune hepatitis, alcoholic liver disease;

2. Liver tumor was detected by liver imaging at the time of screening;

3. patients diagnosed with hepatitis B cirrhosis, that is, those with liver biopsy pathology consistent with liver cirrhosis, or with two or more of the following five criteria, excluding non-cirrhotic portal hypertension: ? imaging examination showed signs of liver cirrhosis and/or portal hypertension; ? Esophagogastric varices were found by endoscopy; ? Liver stiffness was consistent with cirrhosis; ? Blood biochemical examination showed decreased albumin level (< 35 g/L) and/or prolonged prothrombin time (prolonged > 3 seconds compared with the control); ? Blood routine examination showed platelet count < 100×109/L;

4. pregnant or lactating women or those who plan to become pregnant and do not want to use contraception during the study period;

5. neutrophil count <1.5×109/L or platelet count <90×109/L. Patients with creatinine higher than 1.5 times the upper limit of normal;

6. The patients and their close relatives (parents, siblings, etc.) had a history of severe mental illness, especially depression. Severe psychosis is defined as severe depression or psychosis, suicide attempt, hospitalization due to psychosis, or a period of incapacitation due to psychosis;

7. patients with a history of immune-mediated diseases (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis) or abnormally elevated levels of autoimmune antibodies;

8. patients with serious diseases of heart, lung, kidney, brain, blood and other important organs, and patients with other malignant tumors;

9. history of severe epilepsy or current use of antiepileptic drugs. Control of unstable diabetes, hypertension, thyroid disease, etc. A history of severe retinopathy or other evidence of retinopathy;

10. any history of organ transplantation and existing functional graft (except corneal or hair transplantation);

11. patients who are allergic to interferon and its drug components, and who are not suitable for interferon according to the investigator's judgment;

12. Patients deemed by the investigator to be ineligible for the study.

Related Conditions & MeSH terms

• Chronic Hepatitis b
• Fatty Liver
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic
• Liver Diseases
• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Fatty Liver Disease

Intervention

Drug:
• Peg-Interferon a
Peg IFN-a injection was subcutaneously injected 180 µg weekly on the first day of the first week, and NAs was administered daily according to the standard dosage of each drug. For example, HBsAg sero-conversion is achieved within 48 weeks of treatment, Peg IFNa combined with NAs or PEG-IFNa monotherapy was continued for 12 weeks, with a maximum of 96 weeks, and follow-up up to 240 weeks after treatment. If HBsAg negative sero-conversion is not achieved within 48 weeks of treatment, the maximum duration of PEG-IFNa is not more than 96 weeks. If Peg IFNa combined NAs regimen is used, NAs can be continued until the drug can be ended (if HBsAg negative conversion is achieved, NAs should be ended after consolidation therapy not less than 24 weeks; if HBsAg negative conversion is not achieved, NAS should be continued), followed up to 240 weeks after treatment.

Locations

Country	Name	City	State
China	Ningbo No.2 Hospital	Ningbo
China	Ruian People's Hospital	Rui'an
China	The Second Affiliated Hospital of Wenzhou Medical University	Wenzhou
China	Wenzhou People's Hospital	Wenzhou
China	Yueqing People's Hospital	Yueqing

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital of Wenzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HBsAg clearance	HBsAg clearance at 48 weeks of treatment	48 weeks
Secondary	HBsAg clearance at 96 weeks	HBsAg clearance at 96 weeks of treatment	96 weeks
Secondary	Cumulative HBsAg clearance rate	The cumulative clearance rate of HBsAg in chronic hepatitis B patients with different degrees of hepatic steatosis at different treatment nodes; Stratified analysis was performed according to the CAP baseline at enrollment (mild, moderate and severe fatty liver) to explore the correlation between hepatic steatosis and HBsAg clearance rate under different antiviral treatment regimens.	week 24?72?120?144?168?192?216?240
Secondary	Liver Function Tests	the level of ALT and AST	week 24?48?72?96?120?144?168?192?216?240
Secondary	The incidence of liver cirrhosis and liver cancer	The incidence of liver cirrhosis and liver cancer	week 24?48?72?96?120?144?168?192?216?240